PMID- 29778663
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20201216
IS  - 0925-4439 (Print)
IS  - 0925-4439 (Linking)
VI  - 1864
IP  - 9 Pt B
DP  - 2018 Sep
TI  - GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential 
      underlying mechanisms.
PG  - 2814-2821
LID - S0925-4439(18)30182-0 [pii]
LID - 10.1016/j.bbadis.2018.05.012 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a metabolic condition with an elevated impact 
      on cardiovascular (CV) risk. The innovative therapeutic approaches for T2DM - 
      incretin-based therapies (IBTs), including glucagon-like peptide 1 (GLP-1) 
      receptor agonists, have become popular and more widely used in recent years. The 
      available scientific data from clinical studies and clinical practice highlights 
      their beyond glucose-lowering effects, which is achieved without any increase in 
      hypoglycaemia. The former effects include reduction in body weight, lipids, blood 
      pressure, inflammatory markers, oxidative stress, endothelial dysfunction, and 
      subclinical atherosclerosis, thus reducing and potentially preventing CV events. 
      In fact, the introduction of IBTs is one of the key moments in the history of 
      diabetes research and treatment. Such therapeutic strategies allow customization 
      of antidiabetic treatment to each patient's need and therefore obtain better 
      metabolic control with reduced CV risk. The aim of the present paper is to 
      provide a comprehensive overview of the effects of GLP-1RA on various 
      cardiometabolic markers and overall CV risk, with particular attention on recent 
      CV outcome studies and potential mechanisms. In particular, the effects of 
      liraglutide on formation and progression of atherosclerotic plaque and mechanisms 
      explaining its cardioprotective effects are highlighted.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Rizzo, Manfredi
AU  - Rizzo M
AD  - Biomedical Department of Internal Medicine and Medical Specialties, University of 
      Palermo, 90127 Palermo, Italy; Division of Endocrinology, Diabetes and 
      Metabolism, University of South Carolina School of Medicine, Columbia 29203, SC, 
      USA. Electronic address: manfredi.rizzo@unipa.it.
FAU - Nikolic, Dragana
AU  - Nikolic D
AD  - Biomedical Department of Internal Medicine and Medical Specialties, University of 
      Palermo, 90127 Palermo, Italy.
FAU - Patti, Angelo Maria
AU  - Patti AM
AD  - Biomedical Department of Internal Medicine and Medical Specialties, University of 
      Palermo, 90127 Palermo, Italy.
FAU - Mannina, Carlo
AU  - Mannina C
AD  - Biomedical Department of Internal Medicine and Medical Specialties, University of 
      Palermo, 90127 Palermo, Italy.
FAU - Montalto, Giuseppe
AU  - Montalto G
AD  - Biomedical Department of Internal Medicine and Medical Specialties, University of 
      Palermo, 90127 Palermo, Italy. Electronic address: giuseppe.montalto@unipa.it.
FAU - McAdams, Brooke S
AU  - McAdams BS
AD  - Division of Endocrinology, Diabetes and Metabolism, University of South Carolina 
      School of Medicine, Columbia 29203, SC, USA.
FAU - Rizvi, Ali A
AU  - Rizvi AA
AD  - Division of Endocrinology, Diabetes and Metabolism, University of South Carolina 
      School of Medicine, Columbia 29203, SC, USA. Electronic address: 
      ali.rizvi@uscmed.sc.edu.
FAU - Cosentino, Francesco
AU  - Cosentino F
AD  - Unit of Cardiology, Department of Medicine, Karolinska Institute & Karolinska 
      University Hospital Solna, S1:02 171 76 Stockholm, Sweden. Electronic address: 
      francesco.cosentino@ki.se.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180518
PL  - Netherlands
TA  - Biochim Biophys Acta Mol Basis Dis
JT  - Biochimica et biophysica acta. Molecular basis of disease
JID - 101731730
RN  - 0 (Blood Glucose)
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 53AXN4NNHX (semaglutide)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Blood Glucose/drug effects/metabolism
MH  - Cardiovascular Diseases/blood/etiology/metabolism/*prevention & control
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy/metabolism
MH  - Glucagon-Like Peptide-1 Receptor/*agonists/metabolism
MH  - Glucagon-Like Peptides/pharmacology/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - Incretins/*pharmacology/therapeutic use
MH  - Liraglutide/pharmacology/therapeutic use
MH  - Plaque, Atherosclerotic/blood/*drug therapy/etiology/metabolism
OTO - NOTNLM
OT  - Cardiometabolic parameters
OT  - Cardiovascular risk
OT  - Glucagon-like peptide 1 receptor agonists
OT  - Type 2 diabetes mellitus
EDAT- 2018/05/21 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/05/21 06:00
PHST- 2018/02/12 00:00 [received]
PHST- 2018/05/14 00:00 [revised]
PHST- 2018/05/16 00:00 [accepted]
PHST- 2018/05/21 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/05/21 06:00 [entrez]
AID - S0925-4439(18)30182-0 [pii]
AID - 10.1016/j.bbadis.2018.05.012 [doi]
PST - ppublish
SO  - Biochim Biophys Acta Mol Basis Dis. 2018 Sep;1864(9 Pt B):2814-2821. doi: 
      10.1016/j.bbadis.2018.05.012. Epub 2018 May 18.